ANI Pharmaceuticals Inc
F:BSFA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
ANI Pharmaceuticals Inc
F:BSFA
|
US |
|
B
|
Brambles Ltd
OTC:BMBLF
|
AU |
|
Ionic Rare Earths Ltd
ASX:IXR
|
AU |
|
A
|
Airship AI Holdings Inc
NASDAQ:AISP
|
US |
ANI Pharmaceuticals Inc
ANI Pharmaceuticals makes and sells prescription medicines in the United States. Its business includes branded drugs, generic drugs, and a growing set of specialty and rare-disease treatments. It also manufactures some of its own products, which gives it more control over supply for medicines that can be hard to make reliably. The company sells mainly to pharmacies, wholesalers, hospitals, and other healthcare customers that distribute medicines to patients. It earns money when those customers buy its products, and in some cases through licensing or product rights tied to specific drugs. A large part of ANI’s business comes from medicines that have already been approved and are sold after the company takes over or develops the product. What makes ANI different is its focus on older, off-patent medicines and specialized pharmaceutical products rather than broad consumer healthcare. That means it competes through manufacturing know-how, regulatory expertise, and the ability to keep supplying drugs that still have steady medical demand. In simple terms, ANI is a drug maker that finds value in established medicines and the harder-to-manufacture products many larger pharma companies overlook.
ANI Pharmaceuticals makes and sells prescription medicines in the United States. Its business includes branded drugs, generic drugs, and a growing set of specialty and rare-disease treatments. It also manufactures some of its own products, which gives it more control over supply for medicines that can be hard to make reliably.
The company sells mainly to pharmacies, wholesalers, hospitals, and other healthcare customers that distribute medicines to patients. It earns money when those customers buy its products, and in some cases through licensing or product rights tied to specific drugs. A large part of ANI’s business comes from medicines that have already been approved and are sold after the company takes over or develops the product.
What makes ANI different is its focus on older, off-patent medicines and specialized pharmaceutical products rather than broad consumer healthcare. That means it competes through manufacturing know-how, regulatory expertise, and the ability to keep supplying drugs that still have steady medical demand. In simple terms, ANI is a drug maker that finds value in established medicines and the harder-to-manufacture products many larger pharma companies overlook.
Strong Q1: ANI reported total net revenue of $237.5 million, up 20% year over year, and adjusted EBITDA of $63 million, up 24%.
Rare Disease momentum: Cortrophin Gel revenue rose 42% to $75.1 million, with management saying April had the highest new patient starts and monthly volumes dispensed since launch.
Guidance raised: The company lifted 2026 revenue guidance to $1.08 billion to $1.14 billion and adjusted EBITDA guidance to $285 million to $300 million.
Gout expansion: ANI is adding a 90-person commercial team to target acute gouty arthritis flares in primary care and podiatry, with a bigger impact expected in 2027 than 2026.
Harmony deal: ANI recognized $21.5 million of revenue from its Harmony licensing transaction in Q1, including a $15 million upfront fee and initial royalty income.
Capital return: The board authorized a new $100 million share repurchase program, while management said M&A and business development remain the top use for excess cash.
